JCAR 024

Drug Profile

JCAR 024

Alternative Names: ROR-1 directed CAR-T cell therapy

Latest Information Update: 08 Mar 2016

Price : $50

At a glance

  • Originator Fred Hutchinson Cancer Research Center
  • Developer Fred Hutchinson Cancer Research Center; Juno Therapeutics
  • Class Antineoplastics; CAR-T cell therapies
  • Mechanism of Action Protein tyrosine kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Haematological malignancies; Solid tumours

Most Recent Events

  • 29 Feb 2016 Phase-I clinical trials in Haematological malignancies in USA (Parenteral) (Juno Therapeutics pipeline, February 2016)
  • 29 Feb 2016 Phase-I clinical trials in Solid tumours in USA (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top